Turner Pope - SIGNIFICANT short and long term value24 Jun 2020 17:15
Approaching a major inflection point?
Having recently put the necessary financial resources in place, Avacta now
appears positioned to reach a major inflection point. Timing of course is of the
essence for all COVID-19 product developments. Today’s news confirms rapid
progress with the Group’s key POC antigen test, which offers significant
commercial opportunity given its potential to limit global progression of the
disease. Having partnered with a major international development/distribution
group and with advanced talks with suitable manufacturers underway, TPI
considers the potential for the Group to claim a good part of this prospectively
huge international opportunity to be high. Combined with development of its
potential ‘neutralising’ therapy for COVID-19 infection and its BAMSTM diagnostic
test being developed with its partner Adeptrix (Beverly MA, USA), along with the
Group’s core novel cancer immunotherapies that incorporate its two proprietary
platforms, Affimer® biotherapeutics and pre|CISION™ tumour targeted
chemotherapy, Avacta appears to be ideally placed for the creation of significant
short and long term value for shareholders.